β -Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition

Journal of Pathology

Volumn 231, Issue 2, 2013, Pages 210-222

  Oh, Seo Jin ^a,b   Shin, Jung Ho ^c   Kim, Tae Hoon ^a   Lee, Hee Sun ^d   Yoo, Jung Yoon ^a   Ahn, Ji Yeon ^b   Broaddus, Russell R ^e   Taketo, Makoto M ^f   Lydon, John P ^g   Leach, Richard E ^a,h   Lessey, Bruce A ⁱ   Fazleabas, Asgerally T ^a,b   Lim, Jeong Mook ^b   Jeong, Jae Wook ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Seoul National University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Seoul Rachel Fertility Center   (South Korea)

^e UNIVERSITY OF TEXAS   (United States)

^f KYOTO UNIVERSITY   (Japan)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h SPECTRUM HEALTH   (United States)

ⁱ GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

catenin; adenomyosis; epithelial mesenchymal transition; uterus

Indexed keywords

BETA CATENIN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ADENOMYOSIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; MOUSE; MYOMETRIUM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

Β-CATENIN; ADENOMYOSIS; EPITHELIAL-MESENCHYMAL TRANSITION; UTERUS;

ADENOMYOSIS; ANIMALS; BETA CATENIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, MUTANT STRAINS; SIGNAL TRANSDUCTION;

EID: 84883880983     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4224     Document Type: Article

References (77)

1. Tamai K, Togashi K, Ito T, et al., MR imaging findings of adenomyosis: correlation with histopathologic features and diagnostic pitfalls. Radiographics 2005; 25: 21-40.
2. Ferenczy A., Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4: 312-322.
3. Wang PH, Su WH, Sheu BC, et al., Adenomyosis and its variance: adenomyoma and female fertility. Taiwan J Obstet Gynecol 2009; 48: 232-238.
4. Uduwela AS, Perera MA, Aiqing L, et al., Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. Obstet Gynecol Surv 2000; 55: 390-400.
5. Vercellini P, Vigano P, Somigliana E, et al., Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol 2006; 20: 465-477.
6. Koike N, Tsunemi T, Uekuri C, et al., Pathogenesis and malignant transformation of adenomyosis [review]. Oncol Rep 2012; 29: 861-867.
7. Brosens I, Pijnenborg R, Benagiano G,. Defective myometrial spiral artery remodelling as a cause of major obstetrical syndromes in endometriosis and adenomyosis. Placenta 2013; 34: 100-105.
8. Kunz G, Beil D, Huppert P, et al., Adenomyosis in endometriosis- prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2005; 20: 2309-2316.
9. de Souza NM, Brosens JJ, Schwieso JE, et al., The potential value of magnetic resonance imaging in infertility. Clin Radiol 1995; 50: 75-79.
10. Campo S, Campo V, Benagiano G,. Infertility and adenomyosis. Obstet Gynecol Int 2012; 2012: 7806132.
11. Louis LS, Saso S, Chatterjee J, et al., Adenomyosis and infertility. Reprod Biomed Online 2012; 24: 586.
12. Matalliotakis IM, Katsikis IK, Panidis DK,. Adenomyosis: what is the impact on fertility? Curr Opin Obstet Gynecol 2005; 17: 261-264.
13. Devlieger R, D'Hooghe T, Timmerman D,. Uterine adenomyosis in the infertility clinic. Hum Reprod Update 2003; 9: 139-147.
14. Salim R, Riris S, Saab W, et al., Adenomyosis reduces pregnancy rates in infertile women undergoing IVF. Reprod Biomed Online 2012; 25: 273-277.
15. Levgur M, Abadi MA, Tucker A,. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol 2000; 95: 688-691.
16. Sammour A, Pirwany I, Usubutun A, et al., Correlations between extent and spread of adenomyosis and clinical symptoms. Gynecol Obstet Invest 2002; 54: 213-216.
17. Parazzini F, Vercellini P, Panazza S, et al., Risk factors for adenomyosis. Hum Reprod 1997; 12: 1275-1279.
18. Schindler AE,. Progestogen deficiency and endometrial cancer risk. Maturitas 2009; 62: 334-337.
19. Schindler AE,. Hormonal contraceptives and endometriosis/adenomyosis. Gynecol Endocrinol 2010; 26: 851-854.
20. Kazandi M, Zeybek B, Terek MC, et al., Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol 2010; 31: 719-721.
21. Saegusa M, Hashimura M, Yoshida T, et al., β-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001; 84: 209-217.
22. Saegusa M, Okayasu I,. Frequent nuclear β-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001; 194: 59-67.
23. Kobayashi K, Sagae S, Nishioka Y, et al., Mutations of the β-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
24. Ikeda T, Yoshinaga K, Semba S, et al., Mutational analysis of the CTNNB1 (β-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. Oncol Rep 2000; 7: 323-326.
25. Fukuchi T, Sakamoto M, Tsuda H, et al., β-Catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
26. Amant F, Moerman P, Neven P, et al., Endometrial cancer. Lancet 2005; 366: 491-505.
27. Aberle H, Bauer A, Stappert J, et al., β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
28. Palacios J, Gamallo C,. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
29. Cloke B, Huhtinen K, Fusi L, et al., The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. Endocrinology 2008; 149: 4462-4474.
30. Moreno-Bueno G, Hardisson D, Sanchez C, et al., Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene 2002; 21: 7981-7990.
31. Schmalhofer O, Brabletz S, Brabletz T,. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metast Rev 2009; 28: 151-166.
32. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
33. Clevers H., Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-480.
34. Sanchez-Tillo E, Siles L, de Barrios O, et al., Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res 1: 897-912.
35. Jeong JW, Lee HS, Franco HL, et al., β-Catenin mediates glandular formation and dysregulation of β-catenin induces hyperplasia formation in the murine uterus. Oncogene 2009; 28: 31-40.
36. Noyes RW, Hertig AT, Rock J,. Dating the endometrial biopsy. Am J Obstet Gynecol 1975; 122: 262-263.
37. Franco HL, Dai D, Lee KY, et al., WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J 2011; 25: 1176-1187.
38. Kurihara I, Lee DK, Petit FG, et al., COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. PLoS Genet 2007; 3: e102.
39. Lee DK, Kurihara I, Jeong JW, et al., Suppression of ERα activity by COUP-TFII is essential for successful implantation and decidualization. Mol Endocrinol 2010; 24: 930-940.
40. Acloque H, Adams MS, Fishwick K, et al., Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438-1449.
41. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
42. Fan F, Samuel S, Evans KW, et al., Overexpression of Snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med 2012; 1: 5-16.
43. Zhao Y, Yan Q, Long X, et al., Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26: 571-577.
44. Gilles C, Polette M, Mestdagt M, et al., Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Res 2003; 63: 2658-2664.
45. Upton MP, Hirohashi S, Tome Y, et al., Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986; 10: 560-567.
46. Zhou S, Yi T, Liu R, et al., Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteom 2012; 11: M112.017988.
47. Jedryka M, Chrobak A, Chelmonska-Soyta A, et al., Matrix metalloproteinase (MMP)-2 and MMP-9 expression in tumor infiltrating CD3 lymphocytes from women with endometrial cancer. Int J Gynecol Cancer 2012; 22: 1303-1309.
48. Chuang SS, Lin CN, Li CY, et al., Uterine leiomyoma with massive lymphocytic infiltration simulating malignant lymphoma. A case report with immunohistochemical study showing that the infiltrating lymphocytes are cytotoxic T cells. Pathol Res Pract 2001; 197: 135-138.
49. + regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer 2011; 21: 1628-1634.
50. Nelson BH,. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008; 222: 101-116.
51. + myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci 2011; 102: 1724-1733.
52. Greaves P, White IN,. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 503-510.
53. Mori T, Nagasawa H,. Mechanisms of development of prolactin-induced adenomyosis in mice. Acta Anat (Basel) 1983; 116: 46-54.
54. Guttner J., Adenomyosis in mice. Z Versuchstierkd 1980; 22: 249-251.
55. Ostrander PL, Mills KT, Bern HA,. Long-term responses of the mouse uterus to neonatal diethylstilbestrol treatment and to later sex hormone exposure. J Natl Cancer Inst 1985; 74: 121-135.
56. Parrott E, Butterworth M, Green A, et al., Adenomyosis-a result of disordered stromal differentiation. Am J Pathol 2001; 159: 623-630.
57. Harada N, Tamai Y, Ishikawa T, et al., Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 1999; 18: 5931-5942.
58. Soyal SM, Mukherjee A, Lee KY, et al., Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis 2005; 41: 58-66.
59. Tanwar PS, Lee HJ, Zhang L, et al., Constitutive activation of β-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 2009; 81: 545-552.
60. Arango NA, Szotek PP, Manganaro TF, et al., Conditional deletion of β-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 2005; 288: 276-283.
61. Li J, Zhang JV, Cao YJ, et al., Inhibition of the β-catenin signaling pathway in blastocyst and uterus during the window of implantation in mice. Biol Reprod 2005; 72: 700-706.
62. Mohamed OA, Jonnaert M, Labelle-Dumais C, et al., Uterine Wnt/β-catenin signaling is required for implantation. Proc Natl Acad Sci USA 2005; 102: 8579-8584.
63. Rider V, Isuzugawa K, Twarog M, et al., Progesterone initiates Wnt-β-catenin signaling but estradiol is required for nuclear activation and synchronous proliferation of rat uterine stromal cells. J Endocrinol 2006; 191: 537-548.
64. Logan CY, Miller JR, Ferkowicz MJ, et al., Nuclear β-catenin is required to specify vegetal cell fates in the sea urchin embryo. Development 1999; 126: 345-357.
65. Morali OG, Delmas V, Moore R, et al., IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001; 20: 4942-4950.
66. Eger A, Stockinger A, Schaffhauser B, et al., Epithelial-mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of β-catenin and upregulation of β-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000; 148: 173-188.
67. Mariadason JM, Bordonaro M, Aslam F, et al., Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 2001; 61: 3465-3471.
68. Naishiro Y, Yamada T, Takaoka AS, et al., Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of β-catenin/T- cell factor 4-mediated gene transactivation. Cancer Res 2001; 61: 2751-2758.
69. Zeitvogel A, Baumann R, Starzinski-Powitz A,. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 2001; 159: 1839-1852.
70. Qin J, Chen X, Yu-Lee LY, et al., Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res 2010; 70: 8812-8821.
71. Navab R, Gonzalez-Santos JM, Johnston MR, et al., Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. Cancer Res 2004; 64: 5097-5105.
72. Albrecht M, Gillen S, Wilhelm B, et al., Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002; 168: 336-342.
73. Kesse-Adu R, Shousha S,. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004; 17: 646-652.
74. Ogawa H, Iwaya K, Izumi M, et al., Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33: 806-811.
75. Takahara M, Chen S, Kido M, et al., Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes. J Cutan Pathol 2009; 36: 668-674.
76. Bergholt T, Eriksen L, Berendt N, et al., Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod 2001; 16: 2418-2421.
77. Chen YJ, Li HY, Huang CH, et al., Oestrogen-induced epithelial- mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J Pathol 2010; 222: 261-270.